1235. Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing
Session: Poster Abstract Session: Expanded Spectrum - New Antimicrobial Susceptibility Testing
Friday, October 6, 2017
Room: Poster Hall CD
  • IDWeek2017-plazomicin.WGS.pdf (955.8 kB)
  • Background: Plazomicin (PLZ) is a next-generation aminoglycoside (AMG) stable against aminoglycoside-modifying enzymes (AME) that completed Phase 3 studies for complicated urinary tract infections and serious infections due to carbapenem-resistant Enterobacteriaceae (ENT). We evaluated the activity of PLZ and AMGs against ENT collected in US hospitals during 2016.

    Methods: A total of 2,097 ENT were susceptibility (S) tested by CLSI reference broth microdilution methods. E. coli, Klebsiella spp. Enterobacter spp., and P. mirabilis isolates displaying non-S MICs (CLSI criteria) for gentamicin (GEN), amikacin (AMK), and/or tobramycin (TOB) were submitted to WGS, de novo assembly and screening for AME genes.

    Results: Against ENT, PLZ was more active than all 3 clinically available AMGs (Table). PLZ and AMK activities were stable regardless of the infection type; however, differences were observed for GEN and TOB. Bloodstream isolates displayed higher GEN MICs when compared to the other infection sites. TOB activity varied 4-fold, being higher for bloodstream and pneumonia infections and lower for skin/soft tissue and other/unknown specimens. Against 198 isolates carrying 1 or more AME-encoding genes detected among 208 AMG-non-S isolates, the activity of PLZ was 8- to 16-fold greater when compared to the activity of AMK and at least 16-fold higher than the activity of GEN or TOB.


    Conclusion: PLZ was active against ENT isolates from US hospitals regardless of infection type. PLZ displayed activity against isolates carrying AME genes that represent 12.0% of selected species. AME-carrying isolates were considerably more resistant to AMK, GEN, and TOB, highlighting the potential value of PLZ to treat infections caused by these organisms.

    This project has been funded under BARDA Contract No. HHSO100201000046C.


    Mariana Castanheira, PhD1, Lalitagauri M. Deshpande, PhD1, Cory M. Hubler, BS1, Rodrigo E. Mendes, Ph.D.1, Alisa W. Serio, PhD2, Kevin M. Krause, MBA2 and Robert K. Flamm, PhD3, (1)JMI Laboratories, Inc., North Liberty, IA, (2)Achaogen, Inc., South San Francisco, CA, (3)United States Committee on Antimicrobial Susceptibility Testing, Silverton, OR


    M. Castanheira, Achaogen: Research Contractor , Research grant

    L. M. Deshpande, Achaogen: Research Contractor , Research grant

    C. M. Hubler, Achaogen: Research Contractor , Research grant

    R. E. Mendes, Achaogen: Research Contractor , Research grant

    A. W. Serio, Achaogen: Employee , Salary

    K. M. Krause, Achaogen: Employee , Salary

    R. K. Flamm, Achaogen: Research Contractor , Research grant

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.